PolyPeptide - Partner Logo Image

Expertise Partner

The PolyPeptide Group employs approximately 750 staff at sites in Belgium, France, India, Sweden and the USA. The PolyPeptide Group is the world’s largest independent contract manufacturer of therapeutic peptides. The privately-held organization manufactures over one third of all approved peptide drug substances and accounts for over 30% of the sales of outsourced peptide therapeutics worldwide. The Group offers its customers an almost unprecedented long-term security of supply with six GMP facilities worldwide and an exclusive focus on pharmaceutical peptide manufacture.

Untitled design (1)

Expertise Partner

Mytide is the leader in robust, fast, and commercially scalable neoantigen peptide production for drug discovery and personalized therapeutics. Our platform delivers peptides in days, not weeks, by leveraging state-of-the-art chemistry, robotics, and software. Our proprietary approach provides unparalleled documentation, data transparency, and chain of identity (COI) to speed regulatory approval and clinical trial timelines. Mytide’s unique platform meets the capacity, delivery, and regulatory demands of emerging immunotherapies.

Adaptive Biotechnologies - Partner Logo Image

Expertise Partner

Adaptive Biotechnologies is a commercial-stage biotechnology company focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. We believe the adaptive immune system is nature’s most finely tuned diagnostic and therapeutic for most diseases, but the inability to decode it has prevented the medical community from fully leveraging its capabilities. Our proprietary immune medicine platform reveals and translates the massive genetics of the adaptive immune system with scale, precision and speed. We apply our platform to partner with biopharmaceutical companies, inform drug development, and develop clinical diagnostics across our two business areas: Minimal Residual Disease (MRD) and Immune Medicine. Our commercial products and clinical pipeline enable the diagnosis, monitoring, and treatment of diseases such as cancer, autoimmune disorders, and infectious diseases. Our goal is to develop and commercialize immune-driven clinical products tailored to each individual patient.

Neo logo 1

Expertise Partner

Personalis, Inc. is a growing cancer genomics company transforming the development of nextgeneration therapies by providing more comprehensive molecular data about each patient’s cancer and immune response. The company’s NeXT™ Platform is designed to adapt to the complex and evolving understanding of cancer, providing its biopharmaceutical customers with information on all of the approximately 20,000 human genes, together with the immune system, from a single tissue sample. The Personalis Clinical Laboratory is GxP aligned as well as CLIA’88-certified and CAPaccredited.

NEC Oncolmmunity - Partner Logo Image

Industry Development Partner

NEC OncoImmunity is a bioinformatics company offering proprietary machine-learning based software to address the key knowledge gaps in the prediction of bone fide immunogenic neo-antigens for personalized cancer immunotherapy. NEC OncoImmunity is dedicated to develop software solutions that facilitate effective patient selection for cancer immunotherapy, and identify optimal neoantigen targets for truly personalized cancer vaccines & cell therapies in clinically actionable timeframe.

Cayman Chemical - Partner Logo Image

Program Partner

Cayman’s Immunology and Cellular Metabolism Services can complement your drug discovery efforts. Our Immunopeptidome Profiling Services enable deep sequencing analysis of MHC associated peptides by LC-MS/ MS, allowing neoantigen identification in cell lines and tumor tissue. Our Cellular Metabolism Services measure the metabolic response of cells to therapeutics under a wide range of customizable in vitro metabolic environments. Cayman’s expertise in cell culture, immunoassays, antibodies, and assay development provides a complete solution for your research needs.

Almac - Partner Logo Image

Exhibition Partner

Almac has been supplying peptides to the research community and for clinical trials for over 20 years. The field of personlised cancer vaccines requires a new manufacturing paradigm to ensure high throughput manufacture of multiple neoantigens in an appropriate timescale to the required quality and regulatory standards. Almac has created a unique offering to meet all of those demands, which can be tailored to meet specific client needs.

thumbnail_CPC Logo_JPG

Exhibition Partner

Please Add CPC logo
Exhibition Partner
CPC Scientific is a leading peptide CRO/CDMO with capabilities to support early phase screening and development as well as all clinical phases and commercial GMP manufacturing. We have a strong pipeline of programs for our clients in all clinical phases with commercial programs in multiple countries. We are proud to be a valuable partner to many pharmaceutical and biotech companies, governmental and military organizations, and institutions around the globe.

We are excited to share our upcoming New California Peptide Manufacturing facility in Rocklin, California. The 41,000 sq ft facility located at 3880 Atherton Rd, Rocklin, CA 95765 will be utilized to manufacture clinical to commercial grade peptide products for increased manufacturing capacity and will diversify CPC’s supply chain to meet market and client needs. Expanding our manufacturing footprint in the U.S. enables us to continue producing innovative peptide products while providing additional hundreds of kg capacity to specialty peptide APIs more rapidly.

neo logo 2

Exhibition Partner

BCN peptides is an industrial manufacturer with the capacity to produce from milligrams up to multi-kg bulk commercial quantities of GMP pharmaceutical peptides. We have designed and equipped with state-of-the-art technology to meet the unique requirements of neoantigens production. The implementation of automatization systems, together with a fit-for-purpose quality system allows for high-speed production and fully compliant GMP manufacturing with complete traceability of the entire process. We are flexible to meet each customer’s specific demands and we are totally aware of our role as a critical partner in your project. Our participation supplying personalized neoantigen peptides in multiple clinical trials together with our track record and positive regulatory audit reviews from authorities, makes us your partner of choice in the production of Neoantigen Peptides.BCN Peptides - Your partner of choice in the production of Neoantigen Peptides for Immunotherapy.